Drug discovery toward immune checkpoint LILRB4
Conventional immune checkpoint (CP) inhibitors (e.g. PD-1 and CTLA-4 inhibitors) have revolutionized cancer immunotherapy, but are ineffective in approximately 40-80% of patients and have side effects such as autoimmune inflammation. The myeloid CP molecule LILRB4 (B4) has the unique property of being involved in immune evasion of cancer while also being involved in the exacerbation of autoimmune diseases, and is expected to be a new drug target, but its ligand was unknown. The present invention identifies fibronectin (FN) as the only physiological ligand for B4 and finds that immune control is possible by inhibiting the binding of B4 to FN, and relates to a novel CP inhibitor based on this finding. Following patterns can be considered for immunoregulation by blocking the binding between B4 and its ligand FN : (1) FN analog (competitively binds to B4-FN) (2) Anti-B4 antibody (acts on B4 and inhibits B4-FN binding) *Company X has Phase 1b data for its in-house anti-B4 antibody in cancer immunotherapy. Data disclosure may be possible through negotiation (terms to be determined). (3) Anti-FN antibody (acts on FN and inhibits B4-FN binding) Further, B4 as a biomarker for lung cancer patients’ prognosis prediction was verified by our original B4 monoclonal antibody that inhibits B4-FN binding (data not shown).
Inquire About This Product
basic information
For details, please contact us or refer to the PDF.
Price range
Delivery Time
Applications/Examples of results
For details, please contact us or refer to the PDF.
catalog（1）
Download All Catalogs
Company information
The revenue generated from technology transfer is reinvested as new research funding for universities and researchers, and is utilized to create further research outcomes. To ensure the smooth operation of this cycle, known as the "Intellectual Creation Cycle," we will vigorously promote technology transfer. The types of seeds we handle include patents, know-how, databases, and programs. We have established a collaborative framework by signing basic technology transfer agreements with the following universities (as of June 1, 2025): Tohoku University, Hirosaki University, Iwate University, Akita University, Fukushima University, Yamagata University, Tohoku Gakuin University, Iwate Medical University, Fukushima Medical University, Aizu University, Miyagi University, Hokkaido University, Muroran Institute of Technology, and Showa Medical University.
![[Leveling Correction] Leveling correction of concrete floors "Teratec Method"](https://image.mono.ipros.com/public/product/image/d08/1267539002/IPROS70063422645318547243.jpeg?w=280&h=280)
